Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Preferred drug lists and Medicaid prescriptions.

Abdelgawad T, Egbuonu-Davis L.

Pharmacoeconomics. 2006;24 Suppl 3:55-63.

PMID:
17266388
2.

Which physicians are affected most by Medicaid preferred drug lists for statins and antihypertensives?

Ketcham JD, Epstein AJ.

Pharmacoeconomics. 2006;24 Suppl 3:27-40.

PMID:
17266386
3.

Medicaid preferred drug lists: cost containment and side effects.

Headen AE Jr.

Pharmacoeconomics. 2006;24 Suppl 3:1-3. No abstract available.

PMID:
17266384
4.
5.

Medicaid preferred drug lists' costs to physicians.

Ketcham JD, Epstein AJ.

Med Care. 2008 Jan;46(1):9-16.

PMID:
18162850
6.

Preferred drug lists: potential impact on healthcare economics.

Ovsag K, Hydery S, Mousa SA.

Vasc Health Risk Manag. 2008;4(2):403-13. Review.

7.
8.
9.

Impact of Medicaid preferred drug lists on therapeutic adherence.

Ridley DB, Axelsen KJ.

Pharmacoeconomics. 2006;24 Suppl 3:65-78.

PMID:
17266389
10.

Medicaid prescription drug coverage: state efforts to control costs.

Gencarelli DM.

NHPF Issue Brief. 2003 May 10;(790):1-17.

PMID:
12751504
11.

The effect of access restrictions on the vintage of drugs used by Medicaid enrollees.

Lichtenberg FR.

Am J Manag Care. 2005 Jan;11 Spec No:SP7-13. Review.

12.

Pharmaceutical Research and Manufacturers of America v. Walsh: the Supreme Court allows the states to proceed with expanding access to drugs.

Jost TS.

Yale J Health Policy Law Ethics. 2004 Winter;4(1):69-84. Review. No abstract available.

PMID:
15052860
13.
15.

Providing pharmaceutical care for indigent patients: a roundtable discussion.

Hatwig CA, McAllister JC 3rd, Miller DE, Wilson AL.

Am J Health Syst Pharm. 2001 May 15;58(10):867-78. No abstract available.

PMID:
11381491
16.

Benefits and risks of increasing restrictions on access to costly drugs in Medicaid.

Soumerai SB.

Health Aff (Millwood). 2004 Jan-Feb;23(1):135-46.

PMID:
15002636
17.

States' control of prescription drug spending: a heterogeneous approach.

Morden NE, Sullivan SD.

Health Aff (Millwood). 2005 Jul-Aug;24(4):1032-8.

PMID:
16012143
18.

Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

Soumerai SB, Avorn J, Ross-Degnan D, Gortmaker S.

N Engl J Med. 1987 Aug 27;317(9):550-6.

PMID:
3302713
19.

The impact of 1990 Medicaid drug rebates policy on access to prescriptions.

Okunade AA.

J Health Soc Policy. 2001;12(3):33-51.

PMID:
11146982
20.

Pharmaceuticals: pharmaceutical cost controls--2005. End of Year Issue Brief.

Seay M, Varma P.

Issue Brief Health Policy Track Serv. 2005 Dec 31:1-20.

PMID:
16708455

Supplemental Content

Support Center